Walewski, J. Et Al. 2018. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. BRITISH JOURNAL OF HAEMATOLOGY , vol.183, no.3 , 400-410.

Walewski, J., Hellmann, A., Siritanaratkul, N., ÖZSAN, G. H., ÖZCAN, M., Chuncharunee, S., ... Goh, A. S.(2018). Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. BRITISH JOURNAL OF HAEMATOLOGY , vol.183, no.3, 400-410.

Walewski, Jan Et Al. "Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy," BRITISH JOURNAL OF HAEMATOLOGY , vol.183, no.3, 400-410, 2018

Walewski, Jan Et Al. "Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy." BRITISH JOURNAL OF HAEMATOLOGY , vol.183, no.3, pp.400-410, 2018

Walewski, J. Et Al. (2018) . "Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy." BRITISH JOURNAL OF HAEMATOLOGY , vol.183, no.3, pp.400-410.

@article{article, author={Jan Walewski Et Al. }, title={Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy}, journal={BRITISH JOURNAL OF HAEMATOLOGY}, year=2018, pages={400-410} }